Future Horizons for Fibrosing ILDs (Interstitial Lung Diseases): A Focus on PPF and IPF
Released On
June 30, 2025
Expires On
June 30, 2026
Media Type
Internet
Completion Time
60 minutes
Specialty
Pulmonology
Topics
Pulmonary Fibrosis
This activity is provided by The France Foundation.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals.
Credit Available
- Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses - 1.0 Nursing Contact Hour
- Physicians Assistants - 1.0 AAPA Contact Hour
All other health care professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of pulmonologists and other members of the health care team who care for patients with ILDs.
Program Overview
This online, case-based educational activity will help address knowledge and competence gaps related to the pathophysiology, prevalence, and burden of disease of fibrosing ILDs; the early diagnosis and routine assessment of these patients; and the latest developments in the treatments available, including advancements in clinical research and emerging therapies.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Describe the pathophysiology, prevalence, and burden of disease of fibrosing ILDs, such as IPF and PPF
- Identify best practices for early diagnosis and routine assessment of patients with fibrosing ILDs, such as IPF and PPF, in accordance with current guidelines
- Summarize the latest developments in clinical research and emerging therapies for the treatment of fibrosing ILDs, such as IPF and PPF
Faculty
Danielle Antin-Ozerkis, MD
Associate Professor of Medicine (Pulmonary)
Medical Director, Yale ILD Center of Excellence
Pulmonary, Critical Care & Sleep Medicine
Yale School of Medicine
New Haven, CT
Lake D. Morrison, MD
Director, Duke ILD Clinic
Associate Professor of Medicine
Pulmonary, Allergy, and Critical Care Medicine
Duke University School of Medicine
Duke Health
Durham, NC
Accreditation Statement
In support of improving patient care, The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Credit Designation
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The France Foundation designates this activity for 1.0 contact hour.
The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 6/29/2026. PAs should only claim credit commensurate with the extent of their participation.
Disclosures of Conflicts Of Interest
- Danielle Antin-Ozerkis, MD
- Contract Research: Avalyn Pharma, Boehringer Ingelheim Pharmaceuticals, Bristol Myers Squibb, FibroGen, Genentech/Roche, Pliant Therapeutics, and Rein Therapeutics
- Non-CE Consulting: Brainomix
- Lake D. Morrison, MD
- Principal investigator for clinical trials: Avalyn Pharma, Boehringer Ingelheim Pharmaceuticals, Bristol Myers Squibb, Daewoong, Fibrogen, GlaxoSmithKline, Nitto Denko, Orin, Pliant Therapeutics, Promedior, Pulmonary Fibrosis Foundation, and United Therapeutic
- Non-CE Speakers Bureau: Boehringer Ingelheim Pharmaceuticals
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Contact Information
For CME questions please contact: [email protected].